What is HC Wainwright’s Estimate for PepGen FY2025 Earnings?

PepGen, Inc. (NASDAQ:PEPG) – Equities researchers at HC Wainwright raised their FY2025 EPS estimates for PepGen in a research note issued on Thursday, November 13th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($2.64) per share for the year, up from their prior estimate of ($3.07). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s Q4 2025 earnings at ($0.50) EPS, FY2026 earnings at ($2.09) EPS, FY2027 earnings at ($1.40) EPS, FY2028 earnings at ($0.46) EPS and FY2029 earnings at $1.21 EPS.

PepGen (NASDAQ:PEPG) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.11.

Several other analysts have also issued reports on PEPG. Wedbush boosted their target price on PepGen from $7.00 to $9.00 and gave the company an “outperform” rating in a research note on Thursday, September 25th. Guggenheim reissued a “buy” rating and issued a $6.00 price objective on shares of PepGen in a report on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PepGen in a report on Wednesday, October 8th. Stifel Nicolaus increased their target price on shares of PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Finally, Wall Street Zen upgraded shares of PepGen from a “sell” rating to a “hold” rating in a research note on Saturday. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

PepGen Trading Down 3.1%

Shares of PEPG opened at $4.74 on Monday. The stock has a 50 day moving average of $4.00 and a 200 day moving average of $2.29. The company has a market capitalization of $155.47 million, a price-to-earnings ratio of -1.68 and a beta of 1.95. PepGen has a 12 month low of $0.88 and a 12 month high of $6.85.

Institutional Investors Weigh In On PepGen

A number of hedge funds have recently modified their holdings of the business. Viking Global Investors LP increased its position in PepGen by 134.9% in the third quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock worth $16,089,000 after buying an additional 2,000,000 shares in the last quarter. Deep Track Capital LP purchased a new position in shares of PepGen during the 3rd quarter valued at about $5,544,000. Burkehill Global Management LP bought a new position in shares of PepGen during the 3rd quarter valued at approximately $46,000. ADAR1 Capital Management LLC increased its holdings in PepGen by 81.0% in the 3rd quarter. ADAR1 Capital Management LLC now owns 36,842 shares of the company’s stock worth $170,000 after acquiring an additional 16,490 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in PepGen by 45.1% during the 3rd quarter. Two Sigma Investments LP now owns 92,493 shares of the company’s stock worth $427,000 after acquiring an additional 28,753 shares during the period. Institutional investors own 58.01% of the company’s stock.

Insider Buying and Selling at PepGen

In other news, major shareholder Science Enterprises Plc Oxford purchased 200,000 shares of the stock in a transaction dated Tuesday, September 30th. The shares were purchased at an average cost of $3.20 per share, with a total value of $640,000.00. Following the acquisition, the insider directly owned 4,955,388 shares of the company’s stock, valued at $15,857,241.60. This represents a 4.21% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.60% of the stock is owned by insiders.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.